XW133F8
Transfusion Peripheral Vein to New Technology Group 8 with OTL-103, Percutaneous Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | W Anatomical Regions |
| Operation | 1 Transfusion |
| Body Part | 3 Peripheral Vein |
| Approach | 3 Percutaneous |
| Device | F OTL-103 |
| Qualifier | 8 New Technology Group 8 |
Operation Definition
Putting in blood or blood products
Procedure Overview
This family applies specifically to putting blood or blood products into a patient using a New Technology-designated product, distinguishing it from routine transfusions of standard blood components. It exists because certain newer blood-derived products, engineered or processed differently from conventional units, are tracked separately to monitor their use and outcomes.
A patient receiving this kind of transfusion is usually being treated for a condition where standard blood products have proven insufficient, such as certain bleeding disorders or infections, and the care team has opted for a product with novel approval status.
Anatomy & Axis Detail
Peripheral Vein
Transfusion into a peripheral vein under this New Technology code describes infusing a novel blood product or biologic engineered substance through a vein in the arm, hand, leg, or foot rather than a central line. Peripheral veins are chosen for their accessibility and lower procedural risk, making them the default route when the infused product does not require central administration and the patient's peripheral venous access is adequate. Because these transfusions involve substances still classified under New Technology, documentation should identify the specific product, such as an engineered blood component or novel plasma-derived therapy, separately from the vein used for access. Clinicians should also note the specific peripheral vein accessed, since peripheral versus central administration can affect infusion rate, monitoring needs, and how the episode is coded relative to standard transfusion procedures.
Approach: Percutaneous
In New Technology, Percutaneous describes entry into the body via needle or instrument puncture through the skin or a mucous membrane, without a surgical incision, mirroring the same concept in Medical and Surgical. It is distinguished from Open access, which requires a full incision, and from Percutaneous Endoscopic, which adds visualization through the puncture site.
Device / Substance / Technology: OTL-103
OTL-103 denotes administration of an autologous hematopoietic stem cell gene therapy developed to treat Wiskott-Aldrich syndrome by introducing a functional WAS gene into a patient's own blood-forming cells. It is coded here under an investigational product designation, distinguishing it from the similarly structured but disease-specific gene therapies for beta-thalassemia, sickle cell disease, and metachromatic leukodystrophy elsewhere in this list.
Qualifier: New Technology Group 8
Group 8 identifies technologies added to the New Technology section for the 2021-2022 update cycle, tying a given code to that specific approval year. The underlying substance, device, or technique is defined by the other six axis positions, not by the group number itself. Because group numbers simply track chronology, Group 8 differs from Group 7 and Group 9 only in when CMS granted the technology separate recognition.
Coding & Documentation
The documentation needs to specify the exact blood product given, since this family is tied to specific New Technology-approved products rather than blood transfusion in general. Coders should confirm the product name against current approval lists before assigning a code here rather than to a standard transfusion code.
The most common mistake is coding a novel-sounding product under routine transfusion codes, or conversely, assuming any unfamiliar blood product automatically belongs in this family without checking that it actually holds New Technology status.
Commonly Confused With
This is easily confused with standard blood transfusion codes found in the Administration section. The difference comes down entirely to whether the specific product administered has been given New Technology recognition, not the clinical reason for the transfusion or the route used.